New pill shows promise for tough lung cancers
NCT ID NCT07374419
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug, atamparib, in 178 adults with advanced or metastatic non-small cell lung cancer (a common type of lung cancer) that has not responded to standard treatments. The trial has two parts: first, finding the safest dose, then checking how well it works. Participants take atamparib by mouth twice daily.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atamparib (an experimental drug taken by mouth)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced lung cancer whose disease has worsened after standard therapy.
What could go wrong
This is an early-phase trial (Phase Ib/II) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Unit 3.53, 3rd Floor, No. 5, Lane 720 Cailun Road, Pilot Free Trade Zone, Shanghai, P.R.China
Shanghai, Shanghai Municipality, 200000, China